Srougi M, Simon S D, de Góes G M
J Urol. 1985 Jul;134(1):65-9. doi: 10.1016/s0022-5347(17)46983-7.
Disseminated germ cell testicular cancer proved to be highly sensitive to platinum-containing chemotherapy regimens. We present data concerning the treatment of advanced seminoma and nonseminomatous tumors in a developing country. We treated 30 patients with advanced germ cell testis tumors with 3 or 4 cycles of vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum. Surgical resection of residual masses was done 30 days after completion of chemotherapy in 18 patients. The histology of the primary tumor was seminoma in 13 patients and nonseminomatous tumors in 17. Toxicity was mild and no treatment-related deaths occurred. All 13 patients (100 per cent) with seminoma and 12 of 17 patients (71 per cent) with nonseminomatous tumors had a complete response to chemotherapy, and 1 of 17 patients was free of disease after a debulking operation and additional chemotherapy. A total of 3 patients with seminoma and 2 with nonseminomatous tumors had recurrences 5 to 8 months after an initial complete response and received additional chemotherapy (VP-16 regimen) with or without radiotherapy. Complete clinical response was achieved in 4 of 5 patients. Median followup was 24 months (range 8 to 38 months) in the 13 patients with seminoma and 28 months (range 9 to 58 months) in those with nonseminomatous tumors, and 13 (100 per cent) and 12 (71 per cent), respectively, are alive without evidence of disease. These data suggest that the protocol of vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum is highly effective and minimally toxic in the treatment of disseminated germ cell testicular cancer, inducing an 83 per cent long-lasting clinical remission. Seminomas seem to be equally or even more sensitive than nonseminomatous tumors to this platinum-containing chemotherapy regimen. Recurrence after initial complete response can be treated successfully with regimens containing VP-16.
事实证明,播散性睾丸生殖细胞癌对含铂化疗方案高度敏感。我们提供了有关在一个发展中国家治疗晚期精原细胞瘤和非精原细胞瘤的数据。我们用长春花碱、放线菌素D、博来霉素、环磷酰胺和顺铂对30例晚期睾丸生殖细胞肿瘤患者进行了3或4个周期的治疗。18例患者在化疗结束30天后对残留肿块进行了手术切除。原发肿瘤的组织学类型为精原细胞瘤13例,非精原细胞瘤17例。毒性轻微,未发生与治疗相关的死亡病例。所有13例(100%)精原细胞瘤患者和17例中的12例(71%)非精原细胞瘤患者对化疗完全缓解,17例中的1例在减瘤手术和额外化疗后无疾病。共有3例精原细胞瘤患者和2例非精原细胞瘤患者在最初完全缓解后5至8个月复发,并接受了含或不含放疗的额外化疗(VP - 16方案)。5例患者中有4例实现了完全临床缓解。13例精原细胞瘤患者的中位随访时间为24个月(范围8至38个月),17例非精原细胞瘤患者为28个月(范围9至58个月),分别有13例(100%)和12例(71%)存活且无疾病证据。这些数据表明,长春花碱、放线菌素D、博来霉素、环磷酰胺和顺铂方案在治疗播散性睾丸生殖细胞癌方面高效且毒性极小,可诱导83%的长期临床缓解。精原细胞瘤似乎比非精原细胞瘤对这种含铂化疗方案同样敏感甚至更敏感。初始完全缓解后的复发可用含VP - 16的方案成功治疗。